TY - JOUR
T1 - Safety of 5914 intravitreal ziv-aflibercept injections
AU - Singh, Sumit Randhir
AU - Stewart, Michael W.
AU - Chattannavar, Goura
AU - Ashraf, Mohammed
AU - Souka, Ahmed
AU - ElDardeery, Mazen
AU - Wadhwa, Neeraj
AU - Sarvaiya, Chintan
AU - Mansour, Ahmad M.
AU - Marashi, Ameen
AU - Ramchandani, Suresh
AU - Braimah, Imoro Zeba
AU - Bonyadi, Mohammad Hossein Jabbarpoor
AU - Ramezani, Alireza
AU - Soheilian, Masoud
AU - De Oliveira Dias, Joaõ Rafael
AU - De Andrade, Gabriel Costa
AU - Maia, André
AU - Rodrigues, Eduardo Büchele
AU - Farah, Michel Eid
AU - Banker, Alay
AU - Chhablani, Jay
N1 - Publisher Copyright:
© 2019 Author(s).
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Purpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions. Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related. Results A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent. Conclusion This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.
AB - Purpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions. Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related. Results A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent. Conclusion This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.
UR - http://www.scopus.com/inward/record.url?scp=85052707867&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2018-312453
DO - 10.1136/bjophthalmol-2018-312453
M3 - Article
C2 - 30099379
AN - SCOPUS:85052707867
SN - 0007-1161
VL - 103
SP - 805
EP - 810
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 6
ER -